Loading...
Based on early studies, current guidelines recommend renin angiotensin system (RAS) inhibitors for all patients with stable ischemic heart disease and any one of the following conditions: hypertension, diabetes, left ventricular ejection fraction (LVEF) ≤40%, or chronic kidney disease. To evaluate the impact of more-recent studies on the evidence base, researchers conducted a meta-analysis of randomized trials comparing RAS inhibitors with placebo or active controls in patients with stable coronary artery disease (CAD) without heart failure. Included were 24 trials involving 61,961 patients; average follow-up was 3.2 years. Eighteen trials were placebo-controlled, and seven had active controls (calcium-channel antagonists in 4, thiazide diu…